NASDAQ:GNTA Genenta Science (GNTA) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Buy GNTA with Qtrade Free GNTA Stock Alerts $2.59 -0.32 (-11.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.49▼$2.9550-Day Range$2.55▼$4.4952-Week Range$2.20▼$6.81Volume8,097 shsAverage Volume5,414 shsMarket Capitalization$47.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Genenta Science alerts: Email Address Genenta Science MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.93) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.10 out of 5 starsMedical Sector907th out of 913 stocksBiological Products, Except Diagnostic Industry146th out of 146 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Genenta Science. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of Genenta Science have been sold short.Short Interest Ratio / Days to CoverGenenta Science has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genenta Science has recently increased by 30.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenenta Science does not currently pay a dividend.Dividend GrowthGenenta Science does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNTA. Previous Next 0.8 News and Social Media Coverage News SentimentGenenta Science has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genenta Science this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genenta Science insiders have not sold or bought any company stock.Percentage Held by Insiders28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.13% of the stock of Genenta Science is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.09) per share.Price to Book Value per Share RatioGenenta Science has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Genenta Science Stock (NASDAQ:GNTA)Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.Read More GNTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNTA Stock News HeadlinesApril 11, 2024 | cnn.comGenenta Science SpA Sponsored ADRMarch 4, 2024 | msn.comBioVie stock plunges 43% following public offering pricingApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 10, 2024 | markets.businessinsider.comBuy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy PlatformFebruary 8, 2024 | finance.yahoo.comGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsFebruary 3, 2024 | finance.yahoo.comIs Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?November 14, 2023 | finance.yahoo.comIndividual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%August 18, 2023 | au.finance.yahoo.comGenenta Science S.p.A. (GNTA)April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.July 28, 2023 | finance.yahoo.comGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsJuly 8, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn SituationJune 29, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of GliomaJune 29, 2023 | finance.yahoo.comThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaMay 17, 2023 | finance.yahoo.comInsiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the companyMay 16, 2023 | finance.yahoo.comGenenta to Provide Update on Lead Product Temferon™April 26, 2023 | finanznachrichten.deGENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 26, 2023 | finance.yahoo.comGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingApril 3, 2023 | finance.yahoo.comGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor IndicationsMarch 2, 2023 | marketwatch.comGenenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTAMarch 2, 2023 | finance.yahoo.comFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma MultiformeFebruary 24, 2023 | wsj.comGenenta Science S.p.A. ADRFebruary 8, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)February 7, 2023 | finance.yahoo.comGenenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementJanuary 29, 2023 | finance.yahoo.comWe Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business GrowthDecember 8, 2022 | finance.yahoo.comGenenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%November 7, 2022 | finance.yahoo.comGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma PatientsOctober 24, 2022 | finance.yahoo.comGenenta Provides First Half 2022 Business Update and Financial ResultsSee More Headlines Receive GNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNTA CUSIPN/A CIK1838716 Webwww.genenta.com Phone39-02-2643-4681FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio12.25 Quick Ratio12.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book2.14Miscellaneous Outstanding Shares18,220,000Free Float12,936,000Market Cap$47.19 million OptionableNot Optionable Beta0.72 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Pierluigi Paracchi (Age 51)Vice Chairman of the Board, CEO & GM Dr. Luigi Naldini M.D. (Age 65)Ph.D., Co-Founder & Chairman of the Executive Scientific Board Dr. Bernard Rudolph Gentner M.D. (Age 49)Ph.D., Co-Founder & Member of the Executive Scientific Board Mr. Richard B. Slansky (Age 66)Chief Financial Officer Dr. Carlo Russo M.D. (Age 71)Chief Medical Officer & Head of Development Dr. Stefania Mazzoleni Ph.D. (Age 42)Director of Program Development Ms. Barbara Regonini (Age 51)Director of Finance More ExecutivesKey CompetitorsIkena OncologyNASDAQ:IKNAEntera BioNASDAQ:ENTXInstil BioNASDAQ:TILElutiaNASDAQ:ELUTAligos TherapeuticsNASDAQ:ALGSView All Competitors GNTA Stock Analysis - Frequently Asked Questions Should I buy or sell Genenta Science stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNTA shares. View GNTA analyst ratings or view top-rated stocks. How have GNTA shares performed in 2024? Genenta Science's stock was trading at $4.95 at the beginning of the year. Since then, GNTA shares have decreased by 47.7% and is now trading at $2.59. View the best growth stocks for 2024 here. Are investors shorting Genenta Science? Genenta Science saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,900 shares, an increase of 30.0% from the March 31st total of 3,000 shares. Based on an average trading volume of 5,500 shares, the short-interest ratio is currently 0.7 days. View Genenta Science's Short Interest. When did Genenta Science IPO? Genenta Science (GNTA) raised $28 million in an initial public offering (IPO) on Wednesday, December 15th 2021. The company issued 2,400,000 shares at $10.50-$12.50 per share. How do I buy shares of Genenta Science? Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNTA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
